ES2562878T3 - Formulaciones de liberación sostenida de compuestos de risperidona - Google Patents
Formulaciones de liberación sostenida de compuestos de risperidona Download PDFInfo
- Publication number
- ES2562878T3 ES2562878T3 ES08725543.6T ES08725543T ES2562878T3 ES 2562878 T3 ES2562878 T3 ES 2562878T3 ES 08725543 T ES08725543 T ES 08725543T ES 2562878 T3 ES2562878 T3 ES 2562878T3
- Authority
- ES
- Spain
- Prior art keywords
- risperidone
- weight
- fluid composition
- inv
- plgh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical class FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 title claims abstract description 1048
- 239000000203 mixture Substances 0.000 title claims abstract description 478
- 238000009472 formulation Methods 0.000 title claims abstract description 296
- 238000013268 sustained release Methods 0.000 title description 48
- 239000012730 sustained-release form Substances 0.000 title description 48
- 229960001534 risperidone Drugs 0.000 claims abstract description 942
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims abstract description 605
- 229920000642 polymer Polymers 0.000 claims abstract description 187
- 239000012530 fluid Substances 0.000 claims abstract description 126
- 229920001169 thermoplastic Polymers 0.000 claims abstract description 71
- 239000010839 body fluid Substances 0.000 claims abstract description 19
- 210000001124 body fluid Anatomy 0.000 claims abstract description 18
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000007920 subcutaneous administration Methods 0.000 claims abstract description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 9
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000007943 implant Substances 0.000 claims description 217
- 239000003814 drug Substances 0.000 claims description 94
- 238000000034 method Methods 0.000 claims description 59
- 239000007787 solid Substances 0.000 claims description 27
- 229920000728 polyester Polymers 0.000 claims description 19
- 238000013270 controlled release Methods 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 239000004416 thermosoftening plastic Substances 0.000 claims description 13
- 239000012736 aqueous medium Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 201000000980 schizophrenia Diseases 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 6
- 208000024714 major depressive disease Diseases 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 5
- 238000001228 spectrum Methods 0.000 claims description 2
- 230000036470 plasma concentration Effects 0.000 description 222
- 238000012360 testing method Methods 0.000 description 169
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 168
- 241000282472 Canis lupus familiaris Species 0.000 description 139
- 229940079593 drug Drugs 0.000 description 93
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 82
- 229920000747 poly(lactic acid) Polymers 0.000 description 68
- 239000007788 liquid Substances 0.000 description 63
- 238000002347 injection Methods 0.000 description 60
- 239000007924 injection Substances 0.000 description 60
- 229940106887 risperdal Drugs 0.000 description 54
- 239000000243 solution Substances 0.000 description 51
- TVQGDYNRXLTQAP-UHFFFAOYSA-N ethyl heptanoate Chemical compound CCCCCCC(=O)OCC TVQGDYNRXLTQAP-UHFFFAOYSA-N 0.000 description 44
- 241000700159 Rattus Species 0.000 description 41
- 229940116333 ethyl lactate Drugs 0.000 description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 38
- 239000002207 metabolite Substances 0.000 description 36
- 229920001577 copolymer Polymers 0.000 description 34
- 239000002904 solvent Substances 0.000 description 32
- 229940002612 prodrug Drugs 0.000 description 31
- 239000000651 prodrug Substances 0.000 description 31
- 230000000694 effects Effects 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 25
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 25
- 150000003839 salts Chemical class 0.000 description 25
- 206010047700 Vomiting Diseases 0.000 description 23
- 239000000463 material Substances 0.000 description 23
- 241000283973 Oryctolagus cuniculus Species 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000000338 in vitro Methods 0.000 description 21
- 238000011084 recovery Methods 0.000 description 21
- 230000002354 daily effect Effects 0.000 description 20
- 239000000499 gel Substances 0.000 description 20
- 230000003285 pharmacodynamic effect Effects 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 20
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 19
- 229960004046 apomorphine Drugs 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 239000004310 lactic acid Substances 0.000 description 18
- 235000014655 lactic acid Nutrition 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 239000003826 tablet Substances 0.000 description 17
- 230000003474 anti-emetic effect Effects 0.000 description 16
- 230000003247 decreasing effect Effects 0.000 description 16
- 239000011159 matrix material Substances 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 15
- 238000011068 loading method Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 239000012071 phase Substances 0.000 description 14
- 238000000605 extraction Methods 0.000 description 13
- 238000011065 in-situ storage Methods 0.000 description 13
- 239000000654 additive Substances 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 12
- 239000011521 glass Substances 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- -1 6-fluorobenzo [d] isoxazol-3-yl Chemical group 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 206010040880 Skin irritation Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 238000011141 high resolution liquid chromatography Methods 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 229920001306 poly(lactide-co-caprolactone) Polymers 0.000 description 10
- 230000005855 radiation Effects 0.000 description 10
- 231100000475 skin irritation Toxicity 0.000 description 10
- 230000036556 skin irritation Effects 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 230000000144 pharmacologic effect Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000002459 sustained effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 239000004005 microsphere Substances 0.000 description 6
- 150000007522 mineralic acids Chemical class 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229920005862 polyol Polymers 0.000 description 6
- 150000003077 polyols Chemical class 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 208000029560 autism spectrum disease Diseases 0.000 description 5
- 239000004621 biodegradable polymer Substances 0.000 description 5
- 229920002988 biodegradable polymer Polymers 0.000 description 5
- 230000008512 biological response Effects 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 238000001125 extrusion Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000010255 intramuscular injection Methods 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000005096 rolling process Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 208000000323 Tourette Syndrome Diseases 0.000 description 4
- 208000016620 Tourette disease Diseases 0.000 description 4
- PCBOWMZAEDDKNH-HOTGVXAUSA-N [4-(trifluoromethoxy)phenyl]methyl (3as,6as)-2-(3-fluoro-4-sulfamoylbenzoyl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole-5-carboxylate Chemical compound C1=C(F)C(S(=O)(=O)N)=CC=C1C(=O)N1C[C@H]2CN(C(=O)OCC=3C=CC(OC(F)(F)F)=CC=3)C[C@@H]2C1 PCBOWMZAEDDKNH-HOTGVXAUSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 238000006065 biodegradation reaction Methods 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 238000012754 cardiac puncture Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000003880 polar aprotic solvent Substances 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012867 bioactive agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229940095064 tartrate Drugs 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000001069 triethyl citrate Substances 0.000 description 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 3
- 235000013769 triethyl citrate Nutrition 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 2
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 2
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 2
- QZWHWWQXXFOOTD-UHFFFAOYSA-N 5,6,7,8-tetrahydro-4ah-cinnolin-4-one Chemical compound C1CCCC2C(=O)C=NN=C21 QZWHWWQXXFOOTD-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 2
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 229920003178 (lactide-co-glycolide) polymer Polymers 0.000 description 1
- APLNAFMUEHKRLM-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(3,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)N=CN2 APLNAFMUEHKRLM-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000002932 anti-schizophrenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940118398 atridox Drugs 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229960001172 doxycycline hyclate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000000095 emetic effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010078259 luprolide acetate gel depot Proteins 0.000 description 1
- 238000007433 macroscopic evaluation Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 238000006068 polycondensation reaction Methods 0.000 description 1
- 229920000379 polypropylene carbonate Polymers 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94034007P | 2007-05-25 | 2007-05-25 | |
| US940340P | 2007-05-25 | ||
| PCT/US2008/001928 WO2008153611A2 (en) | 2007-05-25 | 2008-02-13 | Sustained delivery formulations of risperidone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2562878T3 true ES2562878T3 (es) | 2016-03-08 |
Family
ID=39496214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08725543.6T Active ES2562878T3 (es) | 2007-05-25 | 2008-02-13 | Formulaciones de liberación sostenida de compuestos de risperidona |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US10010612B2 (https=) |
| EP (2) | EP2152315B1 (https=) |
| JP (3) | JP2010531807A (https=) |
| CN (1) | CN101801415B (https=) |
| AU (1) | AU2008262545B2 (https=) |
| BR (1) | BRPI0811319A2 (https=) |
| CA (1) | CA2687979C (https=) |
| ES (1) | ES2562878T3 (https=) |
| MX (2) | MX337286B (https=) |
| NZ (2) | NZ597621A (https=) |
| WO (1) | WO2008153611A2 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| EP2152315B1 (en) | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| CN101653422B (zh) * | 2008-08-20 | 2013-03-20 | 山东绿叶制药有限公司 | 利培酮缓释微球、其制备方法和用途 |
| CN101584652B (zh) * | 2009-06-19 | 2012-06-20 | 上海医药集团股份有限公司 | 利培酮缓释凝胶注射剂及其制备方法 |
| US20130053405A1 (en) | 2009-10-06 | 2013-02-28 | Ulrich Hersel | Carrier linked paliperidone prodrugs |
| EP2485712A1 (en) | 2009-10-06 | 2012-08-15 | Ascendis Pharma A/S | Subcutaneous paliperidone composition |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| EP2529757B1 (en) * | 2011-05-31 | 2014-01-08 | Laboratorios Farmaceuticos Rovi, S.A. | Paliperidone implant formulation |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| LT2394664T (lt) * | 2010-05-31 | 2016-09-26 | Laboratorios Farmaceuticos Rovi, S.A. | Antipsichozinė injekcinė depozitinė kompozicija |
| PT2394663T (pt) | 2010-05-31 | 2021-11-26 | Farm Rovi Lab Sa | Composições para implantes biodegradáveis injectáveis |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| JP2013543898A (ja) * | 2010-11-24 | 2013-12-09 | デュレクト コーポレイション | 生体分解性薬物送達組成物 |
| CN102058517A (zh) * | 2010-12-31 | 2011-05-18 | 泰州万全医药科技有限公司 | 一种帕潘立酮缓释剂及其制备方法 |
| ES2855349T3 (es) | 2011-04-25 | 2021-09-23 | Shan Dong Luye Pharm Co Ltd | Composición de risperidona de microesferas de liberación controlada |
| LT2529756T (lt) | 2011-05-31 | 2021-07-26 | Laboratorios Farmaceuticos Rovi, S.A. | Risperidono ir (arba) paliperidono implantų kompozicija |
| DE102013011399A1 (de) | 2012-07-31 | 2014-02-06 | Amw Gmbh | Implantat mit Risperidon |
| WO2014052837A1 (en) * | 2012-09-28 | 2014-04-03 | Delpor, Inc. | Device and methods for sustained release of antipsychotic medications |
| US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
| HK1220628A1 (zh) | 2013-03-11 | 2017-05-12 | Durect Corporation | 包含高粘度液体载体的可注射控制释放组合物 |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| WO2015191922A1 (en) | 2014-06-11 | 2015-12-17 | Massachusetts Institute Of Technology | Enteric elastomers |
| US20170266112A1 (en) | 2014-06-11 | 2017-09-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
| NZ731309A (en) | 2014-11-07 | 2022-02-25 | Indivior Uk Ltd | Buprenorphine dosing regimens |
| CN104398474A (zh) * | 2014-11-21 | 2015-03-11 | 内蒙古医科大学附属医院 | 一种利培酮鼻用凝胶剂及其制备方法 |
| CA2983272C (en) | 2015-05-01 | 2023-08-29 | Massachusetts Institute Of Technology | Triggerable shape memory induction devices |
| CA2998504C (en) | 2015-09-21 | 2023-06-20 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulations |
| US20190015415A1 (en) * | 2015-09-30 | 2019-01-17 | Indivior Uk Limited | Methods for treating schizophrenia |
| HK1258050A1 (zh) | 2015-10-23 | 2019-11-01 | Lyndra Therapeutics, Inc. | 用於治疗剂缓释的胃驻留系统及其使用方法 |
| EP4374861A3 (en) | 2015-11-16 | 2024-08-07 | MedinCell S.A. | A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue |
| EP3386488B1 (en) | 2015-12-08 | 2023-09-06 | Lyndra Therapeutics, Inc. | Geometric configurations for gastric residence systems |
| WO2017119928A1 (en) * | 2016-01-08 | 2017-07-13 | Abon Pharmaceuticals, Llc | Long acting injectable formulations |
| AU2017268840B2 (en) | 2016-05-27 | 2022-02-10 | Nortiva Bio, Inc. | Materials architecture for gastric residence systems |
| US11576866B2 (en) | 2016-09-30 | 2023-02-14 | Lyndra Therapeutics, Inc. | Gastric residence systems for sustained delivery of adamantane-class drugs |
| KR102540201B1 (ko) * | 2017-01-04 | 2023-06-08 | 파마덴 에스.에이. | 고분자량의 생분해성 폴리머 제조 방법 |
| US20180235899A1 (en) | 2017-02-17 | 2018-08-23 | Privo Technologies, Inc. | Particle-based multi-layer therapeutic delivery device and method |
| WO2018172850A1 (en) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulaitons |
| US10478403B1 (en) | 2017-05-03 | 2019-11-19 | Privo Technologies, Inc. | Intraoperative topically-applied non-implantable rapid release patch |
| US12023406B2 (en) | 2017-06-09 | 2024-07-02 | Lyndra Therapeutics, Inc. | Gastric residence systems with release rate-modulating films |
| US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
| WO2019059263A1 (en) * | 2017-09-20 | 2019-03-28 | Kao Corporation | HAIR COLORING PROCESS |
| US20190117573A1 (en) * | 2017-10-19 | 2019-04-25 | Hyalo Technologies, LLC | Composition and method of preparation of risperidone extended release preparation |
| US11690806B2 (en) | 2018-05-24 | 2023-07-04 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| US11689849B2 (en) | 2018-05-24 | 2023-06-27 | Nureva, Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
| KR20260007295A (ko) | 2018-05-24 | 2026-01-13 | 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 | 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치 |
| PE20210047A1 (es) | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | Composicion inyectable |
| WO2020154315A1 (en) * | 2019-01-22 | 2020-07-30 | Indivior Uk Limited | Methods for treating schizophrenia |
| LT4027973T (lt) | 2019-09-13 | 2026-01-26 | Medincell S.A. | Vaistų tiekimo kompozicijos |
| EP4069863A4 (en) * | 2019-12-05 | 2024-02-28 | Fresenius Kabi USA, LLC | METHOD FOR ANALYZING DEGARELIX AND RELATED PRODUCTS |
| CN121421961A (zh) * | 2020-01-03 | 2026-01-30 | 派沃技术公司 | 通过直接注射靶细胞群进行治疗的系统和药物组合物 |
| EP4221688A1 (en) * | 2020-09-30 | 2023-08-09 | Tolmar International Limited | Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients |
| US20240100012A1 (en) | 2021-01-18 | 2024-03-28 | Mark Hasleton | Pharmaceutical dosage form |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| CN113267579B (zh) * | 2021-05-18 | 2022-08-30 | 中南民族大学 | 一种监测利培酮血药浓度的方法 |
| KR20240041285A (ko) | 2021-06-01 | 2024-03-29 | 프리보 테크놀로지스, 인코포레이티드 | 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템 |
| JP2024527531A (ja) * | 2021-06-30 | 2024-07-25 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 超長時間作用型薬物送達のための、注入可能、生分解性かつ除去可能なポリマー系の薬物懸濁液 |
| CA3227324A1 (en) | 2021-07-06 | 2023-01-12 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
| US12594236B2 (en) | 2021-07-16 | 2026-04-07 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| US12318387B2 (en) | 2021-07-16 | 2025-06-03 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
| AU2023281232A1 (en) | 2022-05-18 | 2024-10-24 | Laboratorios Farmacéuticos Rovi, S.A. | Prolonged-release injectable compositions for use in treatment with risperidone together with cyp2d6 enzyme inhibitors |
| WO2025124422A1 (zh) * | 2023-12-13 | 2025-06-19 | 长春金赛药业有限责任公司 | 一种原位皮下植入的女性激素调节组合物及其制备方法和应用 |
| CN119950530B (zh) * | 2025-01-24 | 2025-12-05 | 山东新时代药业有限公司 | 一种包含他莫昔芬与人参皂苷的纳米乳及其制备方法 |
Family Cites Families (209)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB806876A (en) | 1956-02-16 | 1959-01-07 | Wellcome Found | Improvements in and relating to disposable hypodermic injection devices |
| GB873526A (en) | 1957-08-14 | 1961-07-26 | Upjohn Co | Fluid compositions comprising (acetyl-salicylic acid)-anhydride |
| GB887872A (en) | 1958-06-25 | 1962-01-24 | Upjohn Co | Improvements in or relating to pharmaceutical preparations |
| DE1467938C3 (de) | 1964-05-22 | 1973-12-20 | F. Hoffmann-La Roche & Co Ag, Basel (Schweiz) | Wasserdispergierbares Arzneipräparat für Tiere |
| JPS5078634A (https=) | 1973-11-16 | 1975-06-26 | ||
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
| US4725442A (en) | 1983-06-17 | 1988-02-16 | Haynes Duncan H | Microdroplets of water-insoluble drugs and injectable formulations containing same |
| US4622219A (en) | 1983-06-17 | 1986-11-11 | Haynes Duncan H | Method of inducing local anesthesia using microdroplets of a general anesthetic |
| US4891225A (en) | 1984-05-21 | 1990-01-02 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
| US4588580B2 (en) | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
| US4534974A (en) | 1984-07-31 | 1985-08-13 | Carter-Wallace, Inc. | Pharmaceutical compositions with codeine |
| US4626539A (en) | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
| US4573995A (en) | 1984-10-09 | 1986-03-04 | Alza Corporation | Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| GB8522453D0 (en) | 1985-09-11 | 1985-10-16 | Lilly Industries Ltd | Chewable capsules |
| JPS62298530A (ja) | 1986-06-16 | 1987-12-25 | Otsuka Pharmaceut Co Ltd | 坐薬用医薬組成物 |
| IT1198449B (it) | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | Esteri di alcoli polivalenti di acido ialuronico |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| CA2002299A1 (en) | 1988-11-10 | 1990-05-10 | Eugene G. Drust | Compositions for the transdermal delivery of buprenorphine salts |
| US5026556A (en) | 1988-11-10 | 1991-06-25 | Norwich Eaton Pharmaceuticals, Inc. | Compositions for the transdermal delivery of pharmaceutical actives |
| US5487897A (en) | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
| US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| DE3927113C2 (de) | 1989-08-17 | 1993-11-25 | Dolorgiet Gmbh & Co Kg | Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung |
| US5096715A (en) | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
| US5558880A (en) | 1989-12-22 | 1996-09-24 | Janssen Pharmaceutica Inc. | Pharmaceutical and other dosage forms |
| US5660851A (en) | 1989-12-26 | 1997-08-26 | Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem | Ocular inserts |
| ES2117642T3 (es) | 1990-05-10 | 1998-08-16 | Bechgaard Int Res | Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles. |
| US5069909A (en) | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
| JPH0456736U (https=) | 1990-09-14 | 1992-05-15 | ||
| US5149543A (en) | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
| WO1992014442A1 (en) | 1991-02-18 | 1992-09-03 | Commonwealth Scientific And Industrial Research Organisation | Composition for use in transdermal administration |
| JP3145742B2 (ja) | 1991-09-19 | 2001-03-12 | 日東電工株式会社 | ゴム系感圧性接着剤とその接着シ―ト |
| AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| WO1993023019A1 (en) | 1992-05-11 | 1993-11-25 | Sri International | Transdermal drug delivery systems and related compositions and methods of use |
| CA2148823C (en) | 1992-11-17 | 1999-03-09 | Welfide Corporation | Sustained release microsphere preparation containing antipsychotic drug and production process thereof |
| TW376319B (en) | 1993-04-28 | 1999-12-11 | Janssen Pharmaceutica Nv | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine |
| JP2651106B2 (ja) | 1993-06-28 | 1997-09-10 | 大同鋼板株式会社 | 金属屋根材の葺設構造及びその葺設方法 |
| NZ260909A (en) | 1993-07-05 | 1995-04-27 | Takeda Chemical Industries Ltd | Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution |
| US5643605A (en) | 1993-10-25 | 1997-07-01 | Genentech, Inc. | Methods and compositions for microencapsulation of adjuvants |
| CN1074923C (zh) | 1993-11-19 | 2001-11-21 | 詹森药业有限公司 | 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类 |
| CA2474701C (en) | 1993-11-19 | 2009-01-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradeable microparticles containing a biologically active agent |
| ATE317690T1 (de) | 1994-04-08 | 2006-03-15 | Qlt Usa Inc | Flüssige zusammensetzungen zur arzneistoffabgabe |
| US5453425A (en) | 1994-07-11 | 1995-09-26 | Janssen Pharmaceutica N.V. | Risperidone oral formulation |
| WO1996021427A1 (en) | 1995-01-09 | 1996-07-18 | Atrix Laboratories, Inc. | Liquid polymer delivery system |
| JP3274579B2 (ja) | 1995-01-12 | 2002-04-15 | 住友製薬株式会社 | 脳血管障害に伴う精神症候治療剤 |
| US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
| US7833543B2 (en) | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
| US5968542A (en) | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
| US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
| PT1006935E (pt) | 1995-06-07 | 2005-06-30 | Durect Corp | Sistema de entrega controlada liquido de alta viscosidade |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6004969A (en) | 1996-04-15 | 1999-12-21 | National Science Council | Transdermal delivery of buprenorphine preparations |
| US5792477A (en) | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
| ATE223206T1 (de) | 1996-05-07 | 2002-09-15 | Alkermes Inc | Verfahren zur herstellung von mikropartikeln |
| JP4346696B2 (ja) | 1996-05-28 | 2009-10-21 | 久光製薬株式会社 | 経皮治療用装置 |
| CN1191824C (zh) | 1996-06-17 | 2005-03-09 | 詹森药业有限公司 | 双面凸的迅速崩解剂型 |
| ATE203157T1 (de) | 1996-12-20 | 2001-08-15 | Alza Corp | Injizierbare depotgelzubereitung und herstellungsverfahren |
| DE19701912C1 (de) | 1997-01-10 | 1998-05-14 | Jenapharm Gmbh | Injizierbares Implantat |
| US5948787A (en) | 1997-02-28 | 1999-09-07 | Alza Corporation | Compositions containing opiate analgesics |
| IT1292396B1 (it) | 1997-06-23 | 1999-02-08 | Lisapharma Spa | Cerotto dermico avente elevata resistenza meccanica,flessibilita' trasparenza e conducibilita' elettrica nel trattamento di affezioni |
| US6622036B1 (en) | 2000-02-09 | 2003-09-16 | Cns Response | Method for classifying and treating physiologic brain imbalances using quantitative EEG |
| DE69916911T2 (de) | 1998-02-10 | 2005-04-21 | Gen Electric | Brenner mit gleichmässiger Brennstoff/Luft Vormischung zur emissionsarmen Verbrennung |
| ES2359973T3 (es) | 1998-03-19 | 2011-05-30 | MERCK SHARP & DOHME CORP. | Composiciones poliméricas líquidas para la liberación controlada de sustancias bioactivas. |
| US7208011B2 (en) | 2001-08-20 | 2007-04-24 | Conor Medsystems, Inc. | Implantable medical device with drug filled holes |
| US6261583B1 (en) | 1998-07-28 | 2001-07-17 | Atrix Laboratories, Inc. | Moldable solid delivery system |
| US6703047B2 (en) | 2001-02-02 | 2004-03-09 | Incept Llc | Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use |
| US6565874B1 (en) * | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| US6355657B1 (en) | 1998-12-30 | 2002-03-12 | Atrix Laboratories, Inc. | System for percutaneous delivery of opioid analgesics |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6291013B1 (en) | 1999-05-03 | 2001-09-18 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
| DE19923551A1 (de) | 1999-05-21 | 2000-11-30 | Lohmann Therapie Syst Lts | Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| DE50112157D1 (de) | 2000-01-11 | 2007-04-19 | Roland Bodmeier | Kit zur implantation enthaltend eine trägerphase und ein lösungsmittel |
| KR100393478B1 (ko) | 2000-03-29 | 2003-08-06 | 주식회사종근당 | 자가유화 매트릭스형 경점막·경피흡수제제 |
| WO2001085731A1 (en) | 2000-05-05 | 2001-11-15 | Rpg Life Sciences Limited | A PROCESS FOR THE PREPARATION OF ANTI-PSCHOTIC 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2,-a]pyrimidin-4-one |
| US6264987B1 (en) | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| WO2002000137A1 (en) | 2000-06-28 | 2002-01-03 | Shukla Atul J | Biodegradable vehicles and delivery systems of biologically active substances |
| DE10035889A1 (de) | 2000-07-24 | 2002-02-14 | Lohmann Therapie Syst Lts | Medizinischer Haftkleber mit einem Gehalt an Zucker-Estern |
| KR100818875B1 (ko) | 2000-08-14 | 2008-04-01 | 테바 파마슈티컬 인더스트리즈 리미티드 | 리스페리돈의 제조 |
| DE10044545A1 (de) | 2000-09-05 | 2002-04-04 | Roland Bodmeier | Retardpartikeldispersion |
| IT250575Y1 (it) | 2000-10-10 | 2003-09-24 | Gimatic Spa | Sistema di guida registrabile per griffe di pinze azionate da unfluido |
| WO2002038185A2 (en) | 2000-11-13 | 2002-05-16 | Atrix Laboratories, Inc. | Injectable sustained release delivery system with loperamide |
| CA2429898C (en) | 2000-11-16 | 2011-02-22 | Durect Corporation | Devices and methods for cholesterol management |
| DK1372729T3 (da) | 2001-02-23 | 2009-06-22 | Genentech Inc | Nedbrydelige polymere til injektion |
| US20040018238A1 (en) | 2001-02-26 | 2004-01-29 | Shukla Atul J | Biodegradable vehicles and delivery systems of biolgically active substances |
| CA2440387A1 (en) | 2001-03-23 | 2002-10-03 | Durect Corporation | Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space |
| US6558702B2 (en) * | 2001-04-13 | 2003-05-06 | Alkermes Controlled Therapeutics, Inc. | Method of modifying the release profile of sustained release compositions |
| GB0112324D0 (en) | 2001-05-21 | 2001-07-11 | Croda Int Plc | Compounds |
| US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| JP2003063954A (ja) | 2001-08-24 | 2003-03-05 | Saitama Daiichi Seiyaku Kk | リザーバー型貼付剤 |
| NZ533434A (en) | 2001-11-14 | 2006-11-30 | Alza Corp | Thixotropic gel composition for injectable deposition |
| KR20040058101A (ko) | 2001-11-14 | 2004-07-03 | 알자 코포레이션 | 카테터 주입가능한 데포 조성물 및 그의 용도 |
| EP1446100B1 (en) | 2001-11-14 | 2011-05-04 | Durect Corporation | Injectable depot compositions and uses thereof |
| US20040258731A1 (en) | 2001-11-21 | 2004-12-23 | Tsuyoshi Shimoboji | Preparation approriate for cartilage tissue formation |
| BRPI0308360B8 (pt) | 2002-03-12 | 2021-05-25 | Ethypharm Sa | composição termossensível sob forma liquida compreendendo substância organogelificante, utilização de uma composição e processo de preparação de uma composição |
| US7041320B1 (en) | 2002-05-31 | 2006-05-09 | Biotek, Inc. | High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence |
| TWI314464B (en) | 2002-06-24 | 2009-09-11 | Alza Corp | Reusable, spring driven autoinjector |
| TWI353854B (en) | 2002-06-25 | 2011-12-11 | Alza Corp | Short duration depot formulations |
| US20040003401A1 (en) | 2002-06-27 | 2004-01-01 | Koninklijke Philips Electronics N.V. | Method and apparatus for using cluster compactness as a measure for generation of additional clusters for stereotyping programs |
| WO2004011065A1 (en) | 2002-07-31 | 2004-02-05 | Alza Corporation | Injection device providing automatic needle retraction |
| DE60325742D1 (de) | 2002-07-31 | 2009-02-26 | Alza Corp | Injizierbare multimodale polymere depotzusammensetzungen und ihre verwendungen |
| WO2004020439A2 (en) | 2002-08-30 | 2004-03-11 | Sunil Sadanand Nadkarni | Improved process for preparation of risperidone |
| US20040105778A1 (en) | 2002-10-04 | 2004-06-03 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
| KR20040034996A (ko) | 2002-10-18 | 2004-04-29 | 한미약품 주식회사 | 리스페리돈의 개선된 제조방법 |
| RU2310450C2 (ru) | 2002-10-25 | 2007-11-20 | Пфайзер Продактс Инк. | Новые депо-препараты для инъекций |
| DE10250084A1 (de) | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| ATE418323T1 (de) | 2002-11-06 | 2009-01-15 | Alza Corp | Depot-formulierungen mit verzögerter freisetzung |
| ATE482695T1 (de) | 2002-12-13 | 2010-10-15 | Durect Corp | Orale darreichungsform mit flüssigen hochviskosen trägersystemen |
| US7501113B2 (en) | 2003-02-04 | 2009-03-10 | Philip Morris Usa Inc. | Aerosol formulations and aerosol delivery of buprenorphine |
| WO2004084868A1 (en) | 2003-03-26 | 2004-10-07 | Egalet A/S | Morphine controlled release system |
| WO2004094415A1 (en) | 2003-04-22 | 2004-11-04 | Synthon B.V. | Risperidone monohydrochloride |
| MXPA05013003A (es) | 2003-05-30 | 2006-03-17 | Alza Corp | Composiciones de deposito elastomerico implantables, usos de las mismas y metodo para elaboracion. |
| JP5229768B2 (ja) | 2003-06-26 | 2013-07-03 | シヴィダ・ユーエス・インコーポレイテッド | Ｉｎ−Ｓｉｔｕゲル化薬物輸送システム |
| TWI357815B (en) | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
| FI20045223A7 (fi) | 2004-06-15 | 2005-12-16 | Bioretec Oy | Monitoiminen biohajoava komposiitti ja kirurginen implantti, joka käsittää mainitun komposiitin |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US20050032781A1 (en) * | 2003-08-06 | 2005-02-10 | Elliot Ehrich | Methods for administering active agents to CYP 2D6 sensitive patients |
| CA2546482A1 (en) | 2003-09-01 | 2005-03-10 | F H Faulding & Co Limited | Compositions and methods for delivery of biologically active agents |
| WO2005037949A2 (en) | 2003-10-07 | 2005-04-28 | Chrysalis Technologies Incorporated | Aerosol formulations of butalbital, lorazepam, ipratropium, baclofen, morphine and scopolamine |
| WO2005117830A1 (en) | 2004-06-04 | 2005-12-15 | Camurus Ab | Liquid depot formulations |
| US20050106214A1 (en) | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
| US20050281879A1 (en) | 2003-11-14 | 2005-12-22 | Guohua Chen | Excipients in drug delivery vehicles |
| US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
| JP4610567B2 (ja) | 2003-12-05 | 2011-01-12 | ゾゲニクス インコーポレーティッド | 無針注射器の送達準備器具 |
| JP2007517042A (ja) | 2003-12-30 | 2007-06-28 | デュレクト コーポレーション | 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント |
| CA2553254C (en) | 2004-01-12 | 2013-12-17 | The Trustees Of The University Of Pennsylvania | Long-term delivery formulations and methods of use thereof |
| US8221778B2 (en) | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| US8329203B2 (en) | 2004-01-12 | 2012-12-11 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| EP1729676A1 (en) | 2004-03-15 | 2006-12-13 | Durect Corporation | Pharmaceutical compositions for administration to a sinus |
| IS7290A (is) | 2004-05-28 | 2005-11-29 | Actavis Group | Lyfjasamsetningar sem innihalda risperidone |
| EP1604693A1 (en) | 2004-06-09 | 2005-12-14 | Scil Technology GmbH | In situ forming scaffold, its manufacturing and use |
| GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
| JP5254616B2 (ja) | 2004-09-13 | 2013-08-07 | クロノ セラピューティクス、インコーポレイテッド | 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達 |
| US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| BRPI0516308A2 (pt) | 2004-10-04 | 2010-06-15 | Qlt Usa Inc | composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida |
| US8246977B2 (en) | 2004-10-21 | 2012-08-21 | Durect Corporation | Transdermal delivery systems |
| CA2586846C (en) | 2004-11-10 | 2013-12-31 | Qlt Usa Inc. | A stabilized polymeric delivery system |
| GB2420976B (en) | 2004-11-19 | 2006-12-20 | Zvi Finkelstein | Therapeutic implant |
| TWI369218B (en) | 2004-12-14 | 2012-08-01 | Novartis Ag | In situ forming implant for animals |
| AU2005316545A1 (en) | 2004-12-15 | 2006-06-22 | Qlt Usa, Inc. | Sustained delivery formulations of octreotide compounds |
| WO2006063430A1 (en) | 2004-12-16 | 2006-06-22 | Miv Therapeutics Inc. | Multi-layer drug delivery device and method of manufacturing same |
| US9415034B2 (en) | 2005-01-05 | 2016-08-16 | National Defense Medical Center | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B) |
| NZ565049A (en) | 2005-06-17 | 2012-02-24 | Vital Health Sciences Pty Ltd | A carrier comprising one or more DI and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
| EP1909689A4 (en) | 2005-07-18 | 2011-11-16 | Univ Pennsylvania | PHARMACEUTICAL IMPLANTS AND METHOD OF USE THEREOF |
| US20070020186A1 (en) | 2005-07-22 | 2007-01-25 | Alpex Pharma S.A. | Solid dosage formulations of narcotic drugs having improved buccal adsorption |
| EP1912627B1 (en) | 2005-08-11 | 2016-08-10 | Promedon S.A. | Composition comprising polymeric, water-insoluble, anionic particles, processes and uses |
| US8852638B2 (en) * | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| CA2627292C (en) | 2005-10-26 | 2012-04-17 | Banner Pharmacaps, Inc. | Hydrophilic vehicle-based dual controlled release matrix system |
| MX2008009125A (es) | 2006-01-18 | 2008-10-23 | Qps Llc | Composiciones farmaceuticas con estabilidad mejorada. |
| US20090022798A1 (en) | 2007-07-20 | 2009-01-22 | Abbott Gmbh & Co. Kg | Formulations of nonopioid and confined opioid analgesics |
| US8765178B2 (en) | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
| EP2068682B1 (en) | 2006-09-25 | 2010-12-22 | Koninklijke Philips Electronics N.V. | Hot water kettle comprising an acoustic member for generating an acoustic signal |
| CN105168186A (zh) | 2006-10-02 | 2015-12-23 | Apr应用制药研究股份公司 | 非粘膜粘着性膜剂型 |
| MX2009003737A (es) | 2006-10-05 | 2009-06-16 | Panacea Biotec Ltd | Composicion inyectable en deposito y su procedimiento de preparacion. |
| SI2079767T1 (sl) | 2006-10-11 | 2015-01-30 | Tolmar Therapeutics, Inc. | Priprava biorazgradljivih poliestrov, ki imajo lastnost majhnega izbruha, s superkritično tekočinsko ekstrakcijo |
| US8076448B2 (en) | 2006-10-11 | 2011-12-13 | Tolmar Therapeutics, Inc. | Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction |
| GB0620661D0 (en) | 2006-10-18 | 2006-11-29 | Pharmasol Ltd | Novel compounds |
| HUE025842T2 (en) | 2007-02-15 | 2016-04-28 | Tolmar Therapeutics Inc | Poly (lactide / glycolide) with reduced fracture properties and methods for producing polymers |
| CA2679316C (en) | 2007-03-02 | 2016-11-29 | Teika Pharmaceutical Co., Ltd. | Morphine composition for transdermal absorption, morphine composition storing unit and transdermal absorption preparation using the same |
| BRPI0809995A2 (pt) | 2007-04-03 | 2015-07-21 | Trimeris Inc | Composição, e, métodos para a liberação prolongada de um peptídeo em um paciente e para melhorar um sintoma associado com uma infecção por hiv |
| DK2167039T3 (en) | 2007-05-18 | 2017-01-09 | Durect Corp | Improved depot formulations |
| EP2152315B1 (en) * | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| AU2008296971B2 (en) | 2007-09-03 | 2014-10-02 | Nanoshift, Llc | Particulate compositions for delivery of poorly soluble drugs |
| SI2200588T1 (sl) | 2007-09-25 | 2019-08-30 | Solubest Ltd. | Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo |
| JP2011506319A (ja) | 2007-12-06 | 2011-03-03 | デュレクト コーポレーション | 疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法 |
| FR2926996B1 (fr) | 2008-01-31 | 2013-06-21 | Ethypharm Sa | Composition pharmaceutique a proprietes gelifiantes contenant un derive de tyrosine |
| CN102231981A (zh) | 2008-02-08 | 2011-11-02 | 昌达生物科技公司 | 蛋白质或肽的缓释给药组合物 |
| WO2009100222A1 (en) | 2008-02-08 | 2009-08-13 | Qps Llc | Non-polymeric compositions for controlled drug delivery |
| JP5286850B2 (ja) | 2008-03-14 | 2013-09-11 | 大日本印刷株式会社 | 液体用紙容器用包装材料およびその包装材料から製造される液体用紙容器 |
| EP2254561A2 (en) | 2008-03-26 | 2010-12-01 | AllTranz Inc. | Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists |
| EP2291174B1 (en) | 2008-06-03 | 2015-01-28 | Tolmar Therapeutics, Inc. | Flowable composition comprising biocompatible oligomer-polymer compositions |
| CN102112107A (zh) | 2008-06-03 | 2011-06-29 | 托马医疗科技公司 | 具有改进的释放动力学特征的控制释放共聚物制剂 |
| US8128951B2 (en) | 2008-09-15 | 2012-03-06 | Cv Ingenuity Corp. | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
| US8114429B2 (en) | 2008-09-15 | 2012-02-14 | Cv Ingenuity Corp. | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
| US8257722B2 (en) | 2008-09-15 | 2012-09-04 | Cv Ingenuity Corp. | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
| JP2012524771A (ja) | 2009-04-23 | 2012-10-18 | ロンドンファーマ リミテッド | 中性油を含む舌下用の医薬組成物 |
| JP5845172B2 (ja) | 2009-05-01 | 2016-01-20 | アデア ファーマスーティカルズ，インコーポレイテッド | 高および低用量薬物の組み合わせを含む口腔内崩壊錠組成物 |
| NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
| FR2949061B1 (fr) | 2009-08-12 | 2013-04-19 | Debregeas Et Associes Pharma | Microgranules flottants |
| ME03396B (me) | 2009-11-18 | 2020-01-20 | Nektar Therapeutics | Oblici kisele soli konjugata polimer-lek |
| US20130023553A1 (en) | 2010-01-12 | 2013-01-24 | Nektar Therapeutics | Pegylated opioids with low potential for abuse and side effects |
| MX343499B (es) | 2010-03-15 | 2016-11-08 | Ipsen Pharma Sas | Composiciones farmaceuticas de ligandos receptores de secretagoga de la hormona de crecimiento. |
| US20110230816A1 (en) | 2010-03-18 | 2011-09-22 | Tyco Healthcare Group Lp | Gels for Transdermal Delivery |
| LT2394664T (lt) | 2010-05-31 | 2016-09-26 | Laboratorios Farmaceuticos Rovi, S.A. | Antipsichozinė injekcinė depozitinė kompozicija |
| PT2394663T (pt) | 2010-05-31 | 2021-11-26 | Farm Rovi Lab Sa | Composições para implantes biodegradáveis injectáveis |
| EP2585092A1 (en) | 2010-06-24 | 2013-05-01 | Torrent Pharmaceuticals Limited | Pharmaceutical composition containing goserelin for in-situ implant |
| ME02367B (me) | 2010-09-21 | 2016-06-20 | Purdue Pharma Lp | Analozi buprenorfina kao agonisti i/ili antagonisti opioidnog receptora |
| CN103200944B (zh) | 2010-11-17 | 2016-05-04 | 赫克萨尔股份公司 | 包含丁丙诺啡的经皮治疗系统 |
| JP2013543898A (ja) | 2010-11-24 | 2013-12-09 | デュレクト コーポレイション | 生体分解性薬物送達組成物 |
| WO2012070027A1 (en) | 2010-11-26 | 2012-05-31 | University Of The Witwatersrand, Johannesburg | A drug delivery device |
| LT2529756T (lt) | 2011-05-31 | 2021-07-26 | Laboratorios Farmaceuticos Rovi, S.A. | Risperidono ir (arba) paliperidono implantų kompozicija |
| TW201338813A (zh) | 2011-12-12 | 2013-10-01 | 洛曼治療系統股份有限公司 | 經皮遞送系統 |
| US9468599B2 (en) | 2011-12-27 | 2016-10-18 | Cmpd Licensing, Llc | Composition and method for compounded therapy |
| US20140134261A1 (en) | 2012-08-21 | 2014-05-15 | Trinity Laboratories, Inc. | Pharmaceutical Compositions Comprising Capsaicin Esters for Treating Pain and Cold Sores |
| RU2513514C1 (ru) | 2012-11-23 | 2014-04-20 | Общество с ограниченной ответственностью "НПК "Трифарма" | Фармацевтическая композиция, содержащая налбуфина гидрохлорид, ее применение для лечения болевого синдрома средней и высокой интенсивности и способ получения фармацевтической композиции |
| CN103142458B (zh) | 2013-01-22 | 2015-09-09 | 莱普德制药有限公司 | 无成瘾性镇痛缓释递药系统的组方与制备方法 |
| US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
| HK1220628A1 (zh) | 2013-03-11 | 2017-05-12 | Durect Corporation | 包含高粘度液体载体的可注射控制释放组合物 |
| US9393211B2 (en) | 2013-03-15 | 2016-07-19 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| IN2013MU03658A (https=) | 2013-11-21 | 2015-09-25 | Akanksha Bindeshwari Prasad Yadav | |
| US10525171B2 (en) | 2014-01-24 | 2020-01-07 | The Spectranetics Corporation | Coatings for medical devices |
-
2008
- 2008-02-13 EP EP08725543.6A patent/EP2152315B1/en not_active Not-in-force
- 2008-02-13 AU AU2008262545A patent/AU2008262545B2/en not_active Ceased
- 2008-02-13 WO PCT/US2008/001928 patent/WO2008153611A2/en not_active Ceased
- 2008-02-13 US US12/602,058 patent/US10010612B2/en active Active
- 2008-02-13 NZ NZ59762108A patent/NZ597621A/xx not_active IP Right Cessation
- 2008-02-13 BR BRPI0811319 patent/BRPI0811319A2/pt not_active Application Discontinuation
- 2008-02-13 JP JP2010509326A patent/JP2010531807A/ja active Pending
- 2008-02-13 MX MX2009012781A patent/MX337286B/es active IP Right Grant
- 2008-02-13 NZ NZ581862A patent/NZ581862A/en not_active IP Right Cessation
- 2008-02-13 ES ES08725543.6T patent/ES2562878T3/es active Active
- 2008-02-13 CN CN200880100394.0A patent/CN101801415B/zh not_active Expired - Fee Related
- 2008-02-13 MX MX2013002428A patent/MX354603B/es unknown
- 2008-02-13 EP EP15000500.7A patent/EP2907524A1/en not_active Ceased
- 2008-02-13 CA CA2687979A patent/CA2687979C/en active Active
-
2013
- 2013-04-18 JP JP2013087247A patent/JP5795606B2/ja not_active Expired - Fee Related
-
2014
- 2014-09-18 US US14/490,034 patent/US9180197B2/en active Active
- 2014-09-18 US US14/490,082 patent/US9186413B2/en active Active
- 2014-09-25 JP JP2014194758A patent/JP2014240436A/ja not_active Withdrawn
-
2017
- 2017-12-29 US US15/858,525 patent/US10376590B2/en active Active
-
2019
- 2019-07-11 US US16/509,287 patent/US11013809B2/en active Active
-
2021
- 2021-04-22 US US17/237,207 patent/US11712475B2/en active Active
-
2022
- 2022-12-19 US US18/083,774 patent/US20230135427A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2562878T3 (es) | Formulaciones de liberación sostenida de compuestos de risperidona | |
| EP3360538B1 (en) | Injectable flowable composition comprising buprenorphine | |
| JP2010531807A5 (https=) | ||
| US10198218B2 (en) | Injectable flowable composition comprising buprenorphine | |
| US8975270B2 (en) | Injectable flowable composition comprising buprenorphine | |
| HK1143731B (en) | Sustained delivery formulations of risperidone compounds | |
| HK40097172A (en) | Injectable flowable composition comprising buprenorphine |